Probiotics nudge blood sugar in the right direction across 47,720 trial participants

Blood sugar control sits at the centre of metabolic health, and when it falters the risk of type 2 diabetes and its complications rises. Probiotics and synbiotics, supplements pairing live bacteria with the fibres that feed them, have been proposed as a way to improve glucose handling through the gut. Several pooled analyses have tested the idea, but their results have pointed in different directions and no settled conclusion had been reached. An umbrella review, which pools the pooled analyses themselves, is a way to see whether the overall evidence adds up to anything.

The researchers searched four databases, the Cochrane Library, PubMed, Web of Science and Scopus, for relevant studies published up to August 2022. They identified 47 eligible meta-analyses of randomised controlled trials, together involving 47,720 participants. They then combined the pooled effects across these analyses, choosing statistical models according to how much the underlying studies disagreed. The outcomes covered four standard measures of glucose control: fasting plasma glucose, fasting plasma insulin, a calculated index of insulin resistance, and glycosylated haemoglobin, a marker of blood sugar over the longer term.

Supplementation was associated with significant reductions across all four measures: fasting plasma glucose, fasting insulin, insulin resistance and glycosylated haemoglobin all fell relative to controls. The effects reached statistical significance in every case, although the underlying analyses disagreed with each other to a substantial degree on most outcomes. A subgroup analysis suggested that people with impaired glucose homeostasis, meaning blood sugar control that is already faltering, stood to benefit the most. The authors conclude that the evidence strongly supports a beneficial effect of probiotic and synbiotic supplementation on glycaemic control.

Individual meta-analyses on probiotics and blood sugar have been inconsistent, which is exactly the problem this umbrella review set out to address. By pooling 47 of them it shifts the overall picture towards a genuine, if modest, benefit. What it cannot resolve is which strains, doses and durations matter, since it works at the level of whole analyses rather than individual trials. It is also worth noting that two of the authors are employed by a large food and drinks company, which readers may reasonably weigh when judging the framing of the conclusion.

This is a reason to take the probiotic and blood sugar story more seriously than any single trial would justify, particularly for people whose glucose control is already impaired, where the signal was strongest. The effects here are group averages, so an individual response could be smaller or absent, and the review does not tell you which product, strain or dose the trials used. For people with healthy glucose control the expected benefit looks smaller. Nothing here suggests probiotics replace the established levers on blood sugar, but as background evidence the case now runs deep.